Loading...
•
Jun 30, 2022
Roivant Sciences Q1 2023 Earnings Report
Roivant Sciences reported financial results for the first quarter ended June 30, 2022.
Key Takeaways
Roivant Sciences reported its financial results for the first quarter ended June 30, 2022. VTAMA launch showed strong early signals with approximately 14,000 prescriptions in the first eleven weeks. Positive topline results were reported from Torii Pharmaceutical and Japan Tobacco's study of tapinarof in atopic dermatitis.
VTAMA launch showed approximately 14,000 prescriptions written in the first eleven weeks.
Positive Phase 3 data reported by Dermavant's Japanese partner for tapinarof in atopic dermatitis.
Enrollment in Priovant's SLE trial is expected to complete in August 2022.
Amy Mahery joined Roivant as Chief Commercial Officer.
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant provided updates on the VTAMA launch, clinical development, and drug discovery.
Positive Outlook
- Dermavant expects to provide updates on the commercial launch of VTAMA for psoriasis on a periodic basis.
- Dermavant expects to report topline data from the Phase 3 trials of VTAMA for the treatment of atopic dermatitis in the first half of calendar year 2023.
- Priovant plans to announce topline results from the potentially registrational trial evaluating brepocitinib for the treatment of patients with SLE in the second half of calendar year 2023.
- Immunovant plans to initiate two pivotal trials to evaluate batoclimab for the treatment of thyroid eye disease in the second half of calendar year 2022, with topline results expected in the first half of calendar year 2025.
- Hemavant plans to announce data from the ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk MDS patients in the second half of calendar year 2023.
Challenges Ahead
- Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the first half of calendar year 2024.